This interactive discussion invites all attendees to reflect on the key insights from the seminar and explore practical ways to refine IPF drug development strategies.

• Which preclinical and translational gaps have been most problematic, and how do we address them?
• What changes are needed in early clinical development to improve the likelihood of success in phase 3?
• How can industry and academia collaborate more effectively to de-risk future programs?

This session will provide a platform for open discussion, allowing attendees to share perspectives and generate actionable next steps for improving IPF clinical development.